A California lawmaker has introduced legislation that would decriminalize psychedelics in the state, the latest bold step in a movement to end America’s war on drugs.
Articles
MindMed Reaches Agreement to Acquire HealthMode, a Leading Machine Learning Digital Medicine Company
MindMed enhances its mental health platform with the acquisition of a machine-learning digital medicine company.
Can LSD cure our pandemic anxiety? MindMed is spending big to find out
While many people will look back on the pandemic as a dark time, it has also spurred some positive developments—most notably in the field of drug development, where miraculous breakthroughs like mRNA vaccines are transforming immunology.
U.S. Psychedelic Drug Legalization: Urgency or Inertia?
Legalized psychedelic drugs are urgently needed to address the Mental Health Crisis. Democrats and Republicans epitomize inertia. The irresistible force meets the immovable object.
Mind Cure Engages Dr. Dan Engle as Primary Investigator for Research in Traumatic Brain Injury with Psychedelics
Dr. Dan Engle, a noted expert in neurology, will lead MINDCURE's psychedelic drug research on traumatic brain injury
Minnesota Marijuana Legalization Bill Approved In First Committee Vote
A bill to legalize marijuana in Minnesota was approved by a House committee on Wednesday—the first of up to a dozen panels that are expected to take up the reform legislation in the weeks to come in advance of a floor vote.
Marijuana Industry Sees Record Jobs Gains In 2020 Despite Pandemic, New Report Shows
The marijuana industry added more than 77,000 jobs over the past year—a 32 percent increase that makes the sector the fastest in job creation compared to any other American industry, according to a new report from the cannabis company Leafly.
MINDCURE's Proprietary Bioinformatics Platform, PsyCollage, Beta Tested and Deployed for Product Discovery and Lead Optimization
MINDCURE adds bioinformatics to its drug development platform.
Transatlantic Capital, Inc. Announces Plan To Initiate Early Phases of Cannabis and Psilocybin Production in the Aftermath of Their Most Recent Land Acquisition
PORTLAND, OR / ACCESSWIRE / February 16, 2021 / Transatlantic Capital Inc. (OTC PINK:TACI) announces their plan to begin early stages of mass Cannabis and Psilocybin Mushroom production by early 2021. As mentioned in a previous announcement from October 22nd, 2020, Transatlantic Inc., or "TACI" finalized a land deal that gave them over 250 acres of rural property in Clarendon, Jamaica which will allow them to safely produce and manufacture their medicinal products.
Mydecine Innovations Group Announces Closing of $17,250,000 Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option
Mydecine closes on CAD$17.25 million, with full over-allotment exercised.
DEA Wants To Know About Applicants’ Hemp And CBD Use, But Only Pre-Legalization
The Drug Enforcement Administration (DEA) wants to know whether its prospective employees or contractors have used hemp or CBD—but only if they used it before December 20, 2018.
Why psychedelics are a more ‘compassionate’ way to treat trauma
THE PAST DECADE has been witness to a renaissance in psychedelics research.
New 5-Year Psychedelics Warrants Offer Exciting Leverage Play
Psychedelic stock warrants have already produced some phenomenal gains for investors. Now a new series of 5-year warrants is trading.
Countdown to Psychedelic Stock Rally, Part 2: Sector-Wide Catalysts
A number of potential sector-wide catalysts for psychedelic stocks are already present or rapidly approaching.
MINDCURE Announces Listing of Warrants
Mind Cure has listed the warrants for trading from its recent financing. Warrants are valid until February 10, 2026, at an exercise price of CAD$0.80.